US OptionsDetailed Quotes
INO250509C3500
- 0.00
- 0.000.00%
15min DelayClose May 9 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest3.50Strike Price0.00Turnover0.00%IV94.44%PremiumMay 9, 2025Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma36.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Inovio Pharmaceuticals Stock Discussion
INOVIO Slashes Losses by $28M as RRP Treatment Shows 50% Complete Response Rate
INOVIO's Revolutionary COVID-19 Antibody Treatment Maintains 100% Efficacy for 72 Weeks
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
Thursday, 13th March at 6:15 pm
• Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint
• No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibod...
“Phase 1/2 data due to be presented at AACR-IO on February 23-26, 2025. BLA submission due in mid-2025. New immunology on Phase 1/2 data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment, noted November 13, 2024.”
｡ﾟ* ҉* ੈ‧₊ ｡ﾟnot financial advice
Breakthrough RRP Treatment Slashes Surgery Need: 28% of Patients Now Surgery-Free in Nature Communications Study
INOVIO Announces Phase 1/2 Trial Results Of INO-3107 For Recurrent Respiratory Papillomatosis With 81% Of Patients Requiring Fewer Surgeries; Plans BLA Submission In Mid-2025 For FDA Accelerated Approval, Aiming To Achieve First US DNA Medicine Approval
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
Complete Response Data: INOVIO's INO-3107 Shows HPV Elimination in RRP Patients
No comment yet